A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate (ALG-1001) as Compared to Avastin and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema

Trial Profile

A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate (ALG-1001) as Compared to Avastin and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs ALG 1001 (Primary) ; Bevacizumab
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms DEL MAR
  • Sponsors Allegro Ophthalmics
  • Most Recent Events

    • 09 Aug 2017 Primary endpoint (Non-inferiority to bevacizumab in mean change in best-corrected visual acuity-STAGE 2) has been met, according to an Allegro Ophthalmics media release.
    • 09 Aug 2017 Results (N=80) from STAGE 2 part pf this trial published in an Allegro Ophthalmics Media Release.
    • 15 Dec 2016 According to Allegro Ophthalmics media release, company completed enrollment in stage 2 of this trial which enrolled 75 patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top